.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Cantor Fitzgerald
Healthtrust
US Department of Justice
Medtronic
Chubb
Argus Health
Express Scripts
Farmers Insurance
Covington

Generated: December 13, 2017

DrugPatentWatch Database Preview

Allergan Company Profile

« Back to Dashboard

What is the competitive landscape for ALLERGAN, and when can generic versions of ALLERGAN drugs launch?

ALLERGAN has one hundred and one approved drugs.

There are one hundred and twenty-three US patents protecting ALLERGAN drugs on ALLERGAN drugs in the past three years.

There are eight hundred and eleven patent family members on ALLERGAN drugs in forty-four countries and ninety-four supplementary protection certificates in twelve countries.

Summary for Allergan

International Patents:811
US Patents:123
Tradenames:86
Ingredients:64
NDAs:101
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
AllerganRESTASIS MULTIDOSEcyclosporineEMULSION;OPHTHALMIC050790-002Oct 27, 2016RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
AllerganLATISSEbimatoprostSOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcTRELSTARtriptorelin pamoateINJECTABLE;INTRAMUSCULAR020715-001Jun 15, 2000RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcFIORINALaspirin; butalbital; caffeineCAPSULE;ORAL017534-005Apr 16, 1986AARXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
AllerganTRIVARIStriamcinolone acetonideINJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL022220-001Jun 16, 2008DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
AllerganPOLYTRIMpolymyxin b sulfate; trimethoprim sulfateSOLUTION/DROPS;OPHTHALMIC050567-001Oct 20, 1988ATRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan HoldingsVIBERZIeluxadolineTABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
AllerganACULAR PRESERVATIVE FREEketorolac tromethamineSOLUTION/DROPS;OPHTHALMIC020811-001Nov 3, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcSAVELLAmilnacipran hydrochlorideTABLET;ORAL022256-003Jan 14, 2009ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcNORINYL 1+35 28-DAYethinyl estradiol; norethindroneTABLET;ORAL-28017565-002Approved Prior to Jan 1, 1982ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
AllerganACZONEdapsoneGEL;TOPICAL021794-001Jul 7, 2005► Subscribe► Subscribe
AllerganACZONEdapsoneGEL;TOPICAL021794-001Jul 7, 2005► Subscribe► Subscribe
Allergan Sales LlcCRINONEprogesteroneGEL;VAGINAL020701-001Jul 31, 1997► Subscribe► Subscribe
Allergan Sales LlcRAPAFLOsilodosinCAPSULE;ORAL022206-001Oct 8, 2008► Subscribe► Subscribe
Allergan Sales LlcKADIANmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL020616-003Jul 3, 1996► Subscribe► Subscribe
Allergan Sales LlcRAPAFLOsilodosinCAPSULE;ORAL022206-002Oct 8, 2008► Subscribe► Subscribe
Allergan Sales LlcALORAestradiolFILM, EXTENDED RELEASE;TRANSDERMAL020655-003Dec 20, 1996► Subscribe► Subscribe
Allergan Sales LlcANDRODERMtestosteroneFILM, EXTENDED RELEASE;TRANSDERMAL020489-002May 2, 1997► Subscribe► Subscribe
AllerganOCUFLOXofloxacinSOLUTION/DROPS;OPHTHALMIC019921-001Jul 30, 1993► Subscribe► Subscribe
Allergan Sales LlcCRINONEprogesteroneGEL;VAGINAL020701-002Jul 31, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ALLERGAN drugs

Drugname Dosage Strength Tradename Submissiondate
dapsoneGel7.5%ACZONE2/13/2017
alcaftadineOphthalmic Solution0.25%LASTACAFT7/30/2014
oxybutynin chlorideGel10%GELNIQUE6/19/2014
milnacipran hydrochlorideTablets12.5 mg, 25 mg, 50 mg, and 100 mgSAVELLA1/14/2013
silodosinCapsules4 mg and 8 mgRAPAFLO10/9/2012
ketorolac tromethamineOpthalmic Solution0.45%ACUVAIL8/24/2011
ketorolac tromethamineOpthalmic Solution0.45%ACUVAIL8/23/2011
bimatoprostOphthalmic Solution0.01%LUMIGAN4/5/2011
gatifloxacinOphthalmic Solution0.5%ZYMAXID12/7/2010
bimatoprosTopical Solution0.03%LATISSE5/3/2010
trospium chlorideExtended-release Capsules60 mgSANCTURA XR3/2/2009
bimatoprostOphthalmic Solution0.03%LUMIGAN12/22/2008
brimonidine tartrate and timolol maleateOphthalmic Solution0.2%/0.5%COMBIGAN11/21/2008
epinastine hydrochlorideOphthalmic Solution0.05%ELESTAT10/14/2008
oxybutyninTransdermal System Extended-re3.9 mg/24 hrsOXYTROL8/19/2008
gatifloxacinOphthalmic Solution0.30%ZYMAR7/19/2007
brimonidine tartrateOphthalmic Solution0.10%ALPHAGAN P12/20/2006
brimonidine tartrateOphthalmic Solution0.15%ALPHAGAN P11/3/2006
ketorolac tromethamineOphthalmic Solution0.40%ACULAR LS1/28/2005

Premature patent expirations for ALLERGAN

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Allergan

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,846,468Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
7,468,065Apparatus for delivery of ocular implants► Subscribe
8,071,120Methods for treating neovascularization and intravitreal implants► Subscribe
6,635,675 Method of treating chronic fatigue syndrome► Subscribe
8,815,929Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists► Subscribe
8,926,953Method of enhancing hair growth► Subscribe
8,980,290Transdermal compositions for anticholinergic agents► Subscribe
7,147,644Apparatus for delivery of ocular implants► Subscribe
7,404,965Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels► Subscribe
6,699,493 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Allergan Drugs

Country Document Number Estimated Expiration
TaiwanI332846► Subscribe
South Korea20160097369► Subscribe
Japan2017031191► Subscribe
Australia2011200423► Subscribe
World Intellectual Property Organization (WIPO)2015091539► Subscribe
European Patent Office1323431► Subscribe
Japan5922515► Subscribe
Japan2017507082► Subscribe
Argentina029567► Subscribe
Norway20052362► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Allergan Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
C0018France► SubscribePRODUCT NAME: ESTRADIOL VALERATE; DIENOGEST; NAT. REGISTRATION NO/DATE: NL35170 20081210; FIRST REGISTRATION: BE327792 20081103
/2001Austria► SubscribePRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
2013025Lithuania► SubscribePRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
13/044Ireland► SubscribePRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
2013 00053Denmark► SubscribePRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
C0008Belgium► SubscribePRODUCT NAME: ESTRADIOL, HEMIHYDRATE; NAT. REGISTRATION NO/DATE: NL 19489 19941107; FIRST REGISTRATION: FR - NL 19489 19941107
2006 00038Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
C/GB97/085United Kingdom► SubscribePRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606
1214076/01Switzerland► SubscribePRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Cantor Fitzgerald
Argus Health
Medtronic
Cipla
Colorcon
Deloitte
Chubb
AstraZeneca
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot